Current Hematologic Malignancy Reports This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
AbstractPurpose of ReviewThere have been significant advances in the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL) over the past two decades. However, the intention of treatment remains control of the disease and delay of progression rather than a cure which remains largely elusive. Considering that CLL is mostly seen in older patients, there are multiple factors that play a role in the selection of CLL beyond the frontline treatment. Here, we review the concept of relapsed CLL, factors that predispose to relapse, and therapeutic options available to this patient population. We also review investigati...
Source: Current Hematologic Malignancy Reports - June 6, 2023 Category: Hematology Source Type: research

New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications
AbstractPurpose of ReviewCutaneous T cell lymphomas (CTCLs) exhibit a wide variety of clinical features, histologic characteristics, and genetic drivers. We review novel molecular findings that inform our understanding of the pathogenesis of CTCL, with a focus on the tumor microenvironment (TME).Recent FindingsThere is increasing evidence challenging the model of TCM:mycosis fungoides (MF) and TEM:S ézary syndrome (SS) phenotype. Phylogenetic analysis performed using whole-exome sequencing (WES) raises the possibility that MF can arise without a common ancestral T cell clone. The detection of ultraviolet (UV) markersignat...
Source: Current Hematologic Malignancy Reports - June 1, 2023 Category: Hematology Source Type: research

Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations
AbstractPurpose of ReviewCCAAT enhancer binding protein A (CEBPA) gene mutation is one of the common genetic alterations in acute myeloid leukemia (AML), which can be associated with sporadic and familial AML.Recent FindingsDue to the recent advances in molecular testing and the prognostic role ofCEBPA mutation in AML, the definition for AML withCEBPA mutation (AML-CEBPA) has significantly changed. This review provides the rationale for the updates on classifications, and the impacts on laboratory evaluation and clinical management for sporadic and familial AML-CEBPA patients. In addition, minimal residual disease assessme...
Source: Current Hematologic Malignancy Reports - June 1, 2023 Category: Hematology Source Type: research

Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents
AbstractPurpose of ReviewTo discuss novel targeted therapies under investigation for treatment of myelodysplastic neoplasms (MDS).Recent FindingsOver the last few years, results of phase 3 trials assessing novel therapies for high-risk MDS have been largely disappointing. Pevonedistat (NEDD-8 inhibitor) and APR-246 (TP53 reactivator) both did not meet trial endpoints. However, early phase trials of BCL-2, TIM3, and CD47 inhibitors have shown exciting data and are currently under phase 3 investigation. Moreover, combination of hypomethylating agents (HMA) with novel therapies targeting the mutational (IDH, FLT3, spliceosome...
Source: Current Hematologic Malignancy Reports - June 1, 2023 Category: Hematology Source Type: research

GATA2 Deficiency: Predisposition to Myeloid Malignancy and Hematopoietic Cell Transplantation
AbstractPurpose of ReviewGATA2 deficiency is a haploinsufficiency syndrome associated with a wide spectrum of disease, including severe monocytopenia and B and NK lymphopenia, predisposition to myeloid malignancies, human papillomavirus infections, and infections with opportunistic organisms, particularly nontuberculous mycobacteria, herpes virus, and certain fungi.GATA2 mutations have variable penetrance and expressivity with imperfect genotype –phenotype correlations. However, approximately 75% of patients will develop a myeloid neoplasm at some point. Allogeneic hematopoietic cell transplantation (HCT) is the only cur...
Source: Current Hematologic Malignancy Reports - May 29, 2023 Category: Hematology Source Type: research

Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer
AbstractPurpose of ReviewThis review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).Recent FindingsThe MPN natural history is driven by uncontrolled clonal myeloproliferation sustained by acquired somatic mutations in driver (JAK2, CALR, and MPL) and non-driver genes, involving epigenetic (e.g., TET2, DNMT3A) regulators, chromatin regulator genes (e.g., ASXL1, EZH2), and splicing machinery ...
Source: Current Hematologic Malignancy Reports - May 24, 2023 Category: Hematology Source Type: research

Pelabresib (CPI-0610): An Exciting Novel Drug for the Treatment of Myelofibrosis
AbstractPurpose of ReviewMyelofibrosis (MF) is a myeloproliferative neoplasm characterized by bone marrow fibrosis, megakaryocyte atypia, and inflammatory cytokine overproduction, resulting in progressive cytopenias, splenomegaly, and high symptom burden. Current backbone of care includes JAK inhibitor (JAKi) therapy, which offers limited benefits and significant discontinuation rates. Targeting the epigenetic modifiers bromodomain and extra-terminal domain (BET) proteins is a novel approach for harnessing the expression of genes involved in critical oncogenic signalling pathways implicated in MF and other malignancies. He...
Source: Current Hematologic Malignancy Reports - May 17, 2023 Category: Hematology Source Type: research

A Pragmatic Approach to Managing Long-Term Adverse Effects in Chronic Myeloid Leukemia Treatment
AbstractPurpose of ReviewLong-term outcomes have significantly improved with treatment of chronic myeloid leukemia. With proper treatment, most patients will achieve similar survival rates compared to an age-matched population. Treatment-free remission is not attainable for over half of patients and chronic treatment carries with it unique challenges. We provide a pragmatic approach to the monitoring and management of chronic adverse effects (AEs).Recent FindingsIn the presence of severe or intolerable AEs, switching tyrosine kinase inhibitors (TKIs) is reasonable but is not without risk. Dose reductions can be attempted w...
Source: Current Hematologic Malignancy Reports - May 16, 2023 Category: Hematology Source Type: research